Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances
Rhea-AI Summary
Victory Square (OTCQX: VSQTF) updated shareholders on its healthcare portfolio following Hydreight Technologies’ July 29, 2026 disclosure about FDA Pharmacy Compounding Advisory Committee recommendations on certain peptide-related bulk drug substances. The committee advised adding six peptides, including BPC-157 and TB-500, to the Section 503A Bulks List, but not Emideltide (DSIP); these recommendations are non-binding and are not FDA approvals.
Victory Square holds about 44.5% of Hydreight, whose U.S. digital healthcare platform spans all 50 states with more than 12,000 VSDHOne licenses sold, 300+ physicians, 3,000+ nurses and over 45 physician-supervised treatments, including peptide-based and GLP-1 therapies. The company also highlighted Insu Therapeutics’ buccal peptide/biologic delivery platform under development and its Pawsible companion animal health initiative, and reminded investors of an Insu-focused shareholder webinar on August 5, 2026.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Victory Square is Hydreight's largest shareholder, holding 23,891,515 common shares, representing approximately
During its meeting held July 23 and 24, 2026, the FDA advisory committee recommended that six peptide-related bulk drug substances—BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon—be included on the Section 503A Bulks List. The committee did not recommend Emideltide (DSIP).
The advisory committee's recommendations are non-binding and do not constitute FDA approval of any bulk drug substance or finished drug product. FDA will determine whether to propose the substances for inclusion on the Section 503A Bulks List through its regulatory rulemaking process.
Hydreight's news release outlines the company's comments regarding the committee's recommendations and notes that Hydreight will continue to monitor the regulatory process while evaluating potential opportunities in consultation with its clinical, pharmacy and legal partners. Shareholders are encouraged to review Hydreight's news release for additional information.
Victory Square's healthcare investments include companies operating in healthcare infrastructure, digital healthcare, drug delivery technology and companion animal health. The following summarizes certain of these investments and previously disclosed activities that may be relevant to shareholders in connection with the recent FDA advisory committee recommendations.
Hydreight Technologies
Victory Square is the largest shareholder of Hydreight Technologies Inc., a digital healthcare platform that connects healthcare providers, pharmacies and patients across
According to Hydreight's most recently reported public disclosures, its platform includes:
- More than 12,000 VSDHOne licenses sold;
- Operations across all 50 U.S. states;
- A nationwide network of more than 300 licensed physicians;
- More than 3,000 licensed nurses;
- A nationwide pharmacy network; and
- More than 45 physician-supervised treatment offerings, including GLP-1 therapies, peptide-based treatments, hormone optimization, NAD+ therapies, IV wellness, sexual health, hair restoration and other personalized healthcare programs.
VSDHOne is Hydreight's proprietary technology platform providing telehealth infrastructure, physician networks, pharmacy fulfillment, compliance and direct-to-consumer healthcare enablement across all 50 U.S. states.
Hydreight has publicly disclosed that peptide-based therapies, including GLP-1 therapies, Sermorelin and Ipamorelin, are currently offered through its physician-supervised healthcare platform.
Hydreight's news release regarding the FDA advisory committee recommendations was issued on July 29, 2026.
Insu Therapeutics
Victory Square also holds an investment in Insu Therapeutics, a development-stage biotechnology company developing a proprietary buccal drug delivery platform for peptide and biologic molecules.
As previously disclosed, Insu's technology is being developed to deliver peptide and biologic medicines through the buccal mucosa (inner cheek) as an alternative route of administration to injectable and traditional oral dosage forms. The platform is designed to support multiple peptide and biologic molecules and remains subject to ongoing research, development, clinical evaluation and applicable regulatory processes.
The Company has previously disclosed that the technology is being developed with objectives that include:
- Providing a needle-free route of administration;
- Eliminating the need for sharps disposal associated with injectable therapies;
- Delivering medicines through the buccal mucosa rather than the gastrointestinal tract;
- Reducing certain administration requirements associated with oral peptide formulations; and
- Providing an alternative delivery platform for peptide and biologic medicines.
Pawsible Ventures
Victory Square is also developing Pawsible, a companion animal health initiative focused on technology-enabled veterinary care, diagnostics, therapeutics and preventative health.
Upcoming Shareholder Webinar
Victory Square previously announced that it will host a live shareholder webinar featuring Insu Therapeutics on Wednesday, August 5, 2026, from 1:15 p.m. PST to 2:00 p.m. PST.
Management of Insu Therapeutics will provide an update on the company's development activities, its proprietary buccal drug delivery platform and current development roadmap. The webinar will conclude with a live question-and-answer session.
Date: Wednesday, August 5, 2026
Time: 1:15 p.m. PST – 2:00 p.m. PST
Registration:
https://us06web.zoom.us/webinar/register/WN_tHRi2nwgSxeHQsydHLFKKg
Shareholders are encouraged to submit questions in advance to IR@victorysquare.com.
On behalf of the Board of Directors,
Shafin Diamond Tejani
Chairman & CEO
Victory Square Technologies Inc.
www.victorysquare.com
ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies Inc. is a publicly traded company that invests in, develops, and supports businesses operating across healthcare infrastructure, digital health, artificial intelligence, immersive technologies, and other emerging sectors.
The Company maintains a portfolio of operating and development-stage businesses, with a particular focus on healthcare infrastructure, software platforms, and technology-enabled services.
Victory Square provides its companies with access to capital, operational support, strategic guidance, and industry relationships to assist in their development and growth.
The Company is headquartered in Vancouver, British Columbia, Canada, and its common shares trade on the Canadian Securities Exchange (CSE: VST), the Frankfurt Stock Exchange (FWB: 6F6), and the OTC Market (OTCQX: VSQTF).
For more information, please visit www.victorysquare.com.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information may be identified by words such as "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions. Forward-looking information in this news release includes, without limitation, statements relating to:
- The Company's strategy and business model
- Portfolio company development and performance
- Platform scaling and utilization
- Capital allocation and monetization initiatives
- Hydreight's publicly disclosed guidance and outlook
- The anticipated benefits of VSDHOne and other platform-based offerings
- Development timelines and regulatory pathways for Insu Therapeutics
- Expansion initiatives across Pawsible Ventures and other portfolio companies
Forward-looking information is based on management's current expectations, estimates, assumptions, and beliefs as of the date of this release, including assumptions regarding:
- Continued partner adoption and transaction volumes
- Stability of regulatory frameworks in applicable jurisdictions
- Availability of capital
- Portfolio company execution
- General economic and market conditions
Forward-looking information relating to Hydreight, including revenue guidance and margin expectations, is based on information publicly disclosed by Hydreight and reflects Hydreight management's expectations regarding partner activity, service mix, and operational capacity. Actual results may differ materially from those anticipated due to a number of factors, including, without limitation:
- Changes in regulatory requirements
- Execution risk at the portfolio company level
- Variability in transaction volumes or partner performance
- Revenue recognition and audit outcomes
- Capital markets conditions
- Clinical development risks
- General economic and industry conditions
There can be no assurance that forward-looking information will prove to be accurate, and readers are cautioned not to place undue reliance on such information.
Except as required by applicable law, the Company does not undertake any obligation to update forward-looking information.
View original content to download multimedia:https://www.prnewswire.com/news-releases/victory-square-provides-update-on-hydreight-and-healthcare-investments-following-fda-advisory-committee-recommendations-on-peptide-related-bulk-drug-substances-302837467.html
SOURCE Victory Square Technologies Inc